Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration
Subscribe To Our Newsletter & Stay Updated
